ReviewThe Journal of antibiotics2017
Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.
Review in The Journal of antibiotics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effects on clinical trial activity of direct funding and taxation policy interventions made by government: A systematic review.PloS one · 2022Pooled it
- Designing eligibility and evaluation criteria for antibacterial pull incentives: a comparative review of implemented and emerging initiatives.The Lancet regional health. Europe · 2026Article
- An evaluation of the US public-private Combating Antibiotic-Resistant Bacteria Accelerator (CARB-X) initiative.Health affairs scholar · 2026Article
- Late-Stage Functionalization of the Rifamycin Core via Click Chemistry Toward New Antibacterial Derivatives.Molecules (Basel, Switzerland) · 2026Article
- Detectable effects of bacterial phylogeny on virulence but not phage efficacy in anISME communications · 2026Article
- No access, no cure: the global crisis of treating extensively drug-resistant carbapenemase-producing organisms.Future microbiology · 2025Article
- Combating Antimicrobial Resistance: Role of Key Stakeholders with Focus on the Pharmaceutical Sector.Pharmaceutical medicine · 2025Review
- Netupitant Exhibits Potent Activity onACS infectious diseases · 2025Article
- Demystifying the commercial determinants of health in antimicrobial resistance through complex system dynamics.Health promotion international · 2025Article
- Advancements in Antibacterial Therapy: Feature Papers.Microorganisms · 2025Review
- An alternative approach to combat multidrug-resistant bacteria: new insights into traditional Chinese medicine monomers combined with antibiotics.Advanced biotechnology · 2025Review
- Infected burn wound healing using Hydroxy-propyl-methyl cellulose gel containing bacteriophages againstIranian journal of microbiology · 2025Article
- Macro- and micro-influencers of antimicrobial costs…What do stewardship programs need to know?Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Discovery of new AMR drugs targeting modulators of antimicrobial activity using in vivo silkworm screening systems.The Journal of antibiotics · 2025Review
- Discovery of antimicrobial activity in chemical extracts derived from unexplored algal-bacterial culture systems and isolates.Scientific reports · 2024Article
- Editorial 15th Anniversary of Pharmaceutics-Improvement of Drug Bioavailability.Pharmaceutics · 2024Article
- Combatting Antibiotic Resistance: Regulatory Exclusivities for New Antibiotic Development in the United States and Europe.Infectious diseases & immunity · 2024Review
- Challenges and opportunities for incentivising antibiotic research and development in Europe.The Lancet regional health. Europe · 2023Review
- Strengthening collaborations at the Biology-Physics interface: trends in antimicrobial photodynamic therapy.Biophysical reviews · 2023Review
- Design, Synthesis, and Structure-Activity Relationship Studies of New Quinone Derivatives as Antibacterial Agents.Antibiotics (Basel, Switzerland) · 2023Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Political momentum and funding for combatting antimicrobial resistance (AMR) continues to build. Numerous major international and national initiatives aimed at financially incentivising the research and development (R&D) of antibiotics have been implemented. However, it remains unclear how to effectively strengthen the current set of incentive programmes to further accelerate antibiotic innovation. Based on a literature review and expert input, this study first identifies and assesses the major international, European Union, US and UK antibiotic R&D funding programmes. These programmes are then evaluated across market and public health criteria necessary for comprehensively improving the antibiotic market. The current set of incentive programmes are an important initial step to improving the economic feasibility of antibiotic development. However, there appears to be a lack of global coordination across all initiatives, which risks duplicating efforts, leaving funding gaps in the value chain and overlooking important AMR goals. This study finds that incentive programmes are overly committed to early-stage push funding of basic science and preclinical research, while there is limited late-stage push funding of clinical development. Moreover, there are almost no pull incentives to facilitate transition of antibiotic products from early clinical phases to commercialisation, focus developer concentration on the highest priority antibiotics and attract large pharmaceutical companies to invest in the market. Finally, it seems that antibiotic sustainability and patient access requirements are poorly integrated into the array of incentive mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.